Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000244 · ClinicalTrials.gov registry record · Phase 2

Effects of Dynorphin 1-13 on Heroin Addiction - 1

A Phase 2 study, sponsored by University of Minnesota.

Completed
Registry status
Phase 2
Development phase

NCT00000244: Completed Phase 2 study, sponsored by University of Minnesota.

NCT00000244 is a Phase 2 study that has completed, run by University of Minnesota. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000244, a Phase 2 study, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.

Interventions

  • DRUG Dynorphin 1 - 13

Trial Details

FieldValue
Start Date 1994-08
Est. Completion 1997-03
Phase Phase 2
University of Minnesota

966 total trials

What the finished NCT00000244 record still lists

NCT00000244 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which Dynorphin 1 - 13 is the first listed.

NCT00000244 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000244 about?

NCT00000244 is a clinical study titled "Effects of Dynorphin 1-13 on Heroin Addiction - 1". The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.

What is the current status of trial NCT00000244?

This trial is currently completed. It is a Phase 2 study. The study started on 1994-08. Estimated completion is 1997-03.

What interventions are being tested in trial NCT00000244?

The interventions under investigation include: Dynorphin 1 - 13 (DRUG).

Who is sponsoring clinical trial NCT00000244?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00000244, the US trial registry maintained by the National Library of Medicine. NCT00000244 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.